Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Obes Surg ; 29(10): 3202-3211, 2019 10.
Artigo em Inglês | MEDLINE | ID: mdl-31214966

RESUMO

PURPOSE: Obesity is associated with increased morbidity and mortality. Weight loss due to gastric bypass (GBP) surgery improves clinical outcomes and may be a cost-effective intervention. To estimate the cost-effectiveness of GBP compared to clinical treatment in severely obese individuals with and without diabetes in the perspective of the Brazilian public health system. MATERIALS AND METHODS: A Markov model was developed to compare costs and outcomes of gastric bypass in an open approach to clinical treatment. Health states were living with diabetes, remission of diabetes, non-fatal and fatal myocardial infarction, and death. We also included the occurrence of complications related to surgery and plastic surgery after the gastric bypass surgery. The direct costs were obtained from primary data collection performed in three public reference centers for obesity treatment. Utility values also derived from this cohort, while transition probabilities came from the international literature. A sensitivity analysis was performed to evaluate uncertainties. The model considered a 10-year time horizon and a 5% discount rate. RESULTS: Over 10 years, GBP increased quality-adjusted life years (QALY) and costs compared to clinical treatment, resulting in an incremental cost-effectiveness ratio (ICER) of Int$1820.17/QALY and Int$1937.73/QALY in individuals with and without diabetes, respectively. Sensitivity analysis showed that utility values and direct costs of treatments were the parameters that affected the most the ICERs. CONCLUSION: The study demonstrated that GBP is a cost-effective intervention for severely obese individuals in the Brazilian public health system perspective, with a better result in individuals with diabetes.


Assuntos
Diabetes Mellitus Tipo 2/cirurgia , Derivação Gástrica/economia , Custos de Cuidados de Saúde/estatística & dados numéricos , Obesidade Mórbida/cirurgia , Índice de Massa Corporal , Brasil , Análise Custo-Benefício , Estudos Transversais , Diabetes Mellitus Tipo 2/economia , Feminino , Humanos , Masculino , Cadeias de Markov , Obesidade/economia , Obesidade/cirurgia , Obesidade/terapia , Obesidade Mórbida/economia , Obesidade Mórbida/terapia , Saúde Pública/economia , Anos de Vida Ajustados por Qualidade de Vida , Redução de Peso
2.
Obes Surg ; 27(12): 3273-3280, 2017 12.
Artigo em Inglês | MEDLINE | ID: mdl-28717859

RESUMO

BACKGROUND: Obesity is a major global epidemic and a burden to society and health systems. This study aimed to estimate and compare the anual costs of clinical and surgical treatment of severe obesity from the perspective of the Brazilian Public Health System. METHODS: An observational and cross-sectional study was performed in three reference centers. Data collection on health resources utilization and productivity loss was carried out through an online questionnaire. Participants were divided in clinical (waiting list for a bariatric surgery) and surgical groups (open Roux-en-Y gastric bypass), and then allocated by the time of surgery (up to 1 year; 1-2 years; 2-3 years; and >3 years). Costs of visits, medications, exams, and surgeries were obtained from government sources. Data on non-medical costs, such as transportation, special diets, and caregivers, were also colleted. Productivity loss was estimated using self-reported income. Costs in local currency (Real) were converted to international dollars (Int$ 2015). RESULTS: Two hundred and seventy-four patients, 140 in surgical group and 134 in clinical group were included. In first postoperative year, the surgical group had higher costs than clinical group (Int$6005.47 [5000.18-8262.36] versus 2148.14 [1412.2-3506.8]; p = 0.0002); however, from the second year, the costs decreased progressively. In the same way, indirect costs decreased significantly after surgery (259.08 [163.63-662.72] versus 368.17 [163.62-687.27]; p = 0.06). CONCLUSION: Total costs were higher in the surgical group in the first 2 years after surgery. However, from the third year on, the costs were lower than in the clinical group.


Assuntos
Fármacos Antiobesidade/economia , Fármacos Antiobesidade/uso terapêutico , Cirurgia Bariátrica/economia , Obesidade Mórbida/economia , Obesidade Mórbida/terapia , Adulto , Cirurgia Bariátrica/estatística & dados numéricos , Brasil/epidemiologia , Custos e Análise de Custo , Estudos Transversais , Dietoterapia/economia , Dietoterapia/estatística & dados numéricos , Feminino , Custos de Cuidados de Saúde , Humanos , Masculino , Pessoa de Meia-Idade , Obesidade Mórbida/epidemiologia , Saúde Pública/economia , Programas de Redução de Peso/economia , Programas de Redução de Peso/estatística & dados numéricos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA